Skip to main content
Erschienen in: Cancer Causes & Control 8/2015

01.08.2015 | Original paper

Associations between diabetes medication use and risk of second breast cancer events and mortality

verfasst von: Gregory S. Calip, Onchee Yu, Kent F. Hoskins, Denise M. Boudreau

Erschienen in: Cancer Causes & Control | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Diabetes and certain diabetes medications have been shown to influence breast cancer (BC) risk. Less is known about their relation to BC outcomes. Our objective was to evaluate the effects of diabetes and diabetes medications on risk of second breast cancer events (SBCE) and mortality.

Methods

This population-based cohort study was conducted among women diagnosed with early-stage (I–II) BC and enrolled in an integrated health plan. Exposures of interest were diabetes and medication classes including insulin, metformin, and sulfonylureas. Outcomes of interest were SBCE defined as recurrence or second primary BC, BC-specific mortality, and all-cause mortality. We used multivariable Cox proportional hazards models to estimate hazard ratios (HR) and 95 % confidence intervals (CI) for diabetes and medication use while accounting for potential confounders and competing risks.

Results

Among 4,216 women, 13 % developed SBCE during a median follow-up of 6.3 years. 610 women had diabetes of which 76 % used oral diabetes medication and/or insulin. Findings suggested that diabetes increased the risk of recurrence (HR = 1.57; 95 % CI 1.09–2.25) but not overall SBCE (HR = 1.29; 95 % CI 0.94–1.76) or second primary BC (HR = 0.74; 95 % CI 0.39–1.41). Among women with diabetes, insulin use was associated with increased risks of recurrence (HR = 1.94; 95 % CI 1.08–3.48) and all-cause mortality (HR = 2.33; 95 % CI 1.70–3.20). Metformin use was associated with lower all-cause mortality (HR = 0.55; 95 % CI 0.38–0.79).

Conclusions

Our findings show an association between diabetes and increased recurrence risk, and risk may be greater among insulin users. Metformin may reduce all-cause mortality among BC survivors. Given the growing breast cancer survivor population, further research in larger, more diverse populations is warranted.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat American Cancer Society (2013) Breast cancer facts and figures 2013–2014. American Cancer Society Inc, Atlanta American Cancer Society (2013) Breast cancer facts and figures 2013–2014. American Cancer Society Inc, Atlanta
3.
Zurück zum Zitat Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. Diab Care 33(7):1674–1685. doi:10.2337/dc10-0666 CrossRef Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. Diab Care 33(7):1674–1685. doi:10.​2337/​dc10-0666 CrossRef
9.
Zurück zum Zitat Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30(23):2844–2852. doi:10.1200/JCO.2011.39.7505 PubMedCentralPubMedCrossRef Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30(23):2844–2852. doi:10.​1200/​JCO.​2011.​39.​7505 PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55(1):51–62. doi:10.1007/s00125-011-2312-4 PubMedCentralPubMedCrossRef Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55(1):51–62. doi:10.​1007/​s00125-011-2312-4 PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Lind M, Fahlen M, Eliasson B, Oden A (2012) The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diab 6(1):53–59. doi:10.1016/j.pcd.2011.10.004 CrossRef Lind M, Fahlen M, Eliasson B, Oden A (2012) The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diab 6(1):53–59. doi:10.​1016/​j.​pcd.​2011.​10.​004 CrossRef
14.
Zurück zum Zitat Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M (2011) Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diab Care 34(9):1965–1971. doi:10.2337/dc11-0699 CrossRef Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M (2011) Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diab Care 34(9):1965–1971. doi:10.​2337/​dc11-0699 CrossRef
17.
Zurück zum Zitat Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297–3302. doi:10.1200/JCO.2009.19.6410 PubMedCentralPubMedCrossRef Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297–3302. doi:10.​1200/​JCO.​2009.​19.​6410 PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30(21):2593–2600. doi:10.1200/JCO.2011.39.3769 PubMedCrossRef Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30(21):2593–2600. doi:10.​1200/​JCO.​2011.​39.​3769 PubMedCrossRef
19.
Zurück zum Zitat Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N (2012) Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 55(3):644–653. doi:10.1007/s00125-011-2429-5 PubMedCentralPubMedCrossRef Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N (2012) Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 55(3):644–653. doi:10.​1007/​s00125-011-2429-5 PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49(6):999–1005PubMedCrossRef Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49(6):999–1005PubMedCrossRef
22.
Zurück zum Zitat Mayer D, Chantelau E (2010) Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 116(2):73–78. doi:10.3109/13813451003631439 PubMedCrossRef Mayer D, Chantelau E (2010) Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 116(2):73–78. doi:10.​3109/​1381345100363143​9 PubMedCrossRef
23.
26.
Zurück zum Zitat Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 223–239 Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 223–239
27.
Zurück zum Zitat Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38(7–8):1317–1318. doi:10.1345/aph.1D569 PubMedCrossRef Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38(7–8):1317–1318. doi:10.​1345/​aph.​1D569 PubMedCrossRef
29.
Zurück zum Zitat Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 83(4):803–819. doi:10.1016/S0039-6109(03)00034-3 PubMedCrossRef Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 83(4):803–819. doi:10.​1016/​S0039-6109(03)00034-3 PubMedCrossRef
32.
Zurück zum Zitat Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM (1999) Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14(6):270–277PubMedCrossRef Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM (1999) Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14(6):270–277PubMedCrossRef
33.
Zurück zum Zitat Newton KM, LaCroix AZ, Heckbert SR, Abraham L, McCulloch D, Barlow W (2003) Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes. Diab Care 26(10):2810–2816CrossRef Newton KM, LaCroix AZ, Heckbert SR, Abraham L, McCulloch D, Barlow W (2003) Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes. Diab Care 26(10):2810–2816CrossRef
34.
Zurück zum Zitat Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C (1999) The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 52(3):199–207PubMedCrossRef Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C (1999) The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 52(3):199–207PubMedCrossRef
35.
Zurück zum Zitat Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, European Association for Study of Diabetes (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diab Care 32(1):193–203. doi:10.2337/dc08-9025 CrossRef Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, European Association for Study of Diabetes (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diab Care 32(1):193–203. doi:10.​2337/​dc08-9025 CrossRef
36.
Zurück zum Zitat Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127–2132. doi:10.1200/JCO.2006.10.3523 PubMedCrossRef Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127–2132. doi:10.​1200/​JCO.​2006.​10.​3523 PubMedCrossRef
37.
38.
Zurück zum Zitat Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM (2012) Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202–1211. doi:10.1002/cncr.26439 PubMedCentralPubMedCrossRef Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM (2012) Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202–1211. doi:10.​1002/​cncr.​26439 PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL (2013) Association between metformin therapy and mortality after breast cancer: a population-based study. Diab Care 36(10):3018–3026. doi:10.2337/dc12-2535 CrossRef Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL (2013) Association between metformin therapy and mortality after breast cancer: a population-based study. Diab Care 36(10):3018–3026. doi:10.​2337/​dc12-2535 CrossRef
40.
Zurück zum Zitat Peeters PJ, Bazelier MT, Vestergaard P, Leufkens HG, Schmidt MK, de Vries F, De Bruin ML (2013) Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 8(5):357–363PubMedCrossRef Peeters PJ, Bazelier MT, Vestergaard P, Leufkens HG, Schmidt MK, de Vries F, De Bruin ML (2013) Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 8(5):357–363PubMedCrossRef
41.
42.
Zurück zum Zitat Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619PubMedCrossRef Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619PubMedCrossRef
43.
Zurück zum Zitat Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM (2015) Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf 24(1):75–85. doi:10.1002/pds.3660 PubMedCrossRef Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM (2015) Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf 24(1):75–85. doi:10.​1002/​pds.​3660 PubMedCrossRef
45.
Zurück zum Zitat Sabatino SA, Thompson TD, Wu XC, Fleming ST, Kimmick GG, Trentham-Dietz A, Cress R, Anderson RT (2014) The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. Breast Cancer Res Treat 146(1):199–209. doi:10.1007/s10549-014-2998-3 PubMedCrossRef Sabatino SA, Thompson TD, Wu XC, Fleming ST, Kimmick GG, Trentham-Dietz A, Cress R, Anderson RT (2014) The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. Breast Cancer Res Treat 146(1):199–209. doi:10.​1007/​s10549-014-2998-3 PubMedCrossRef
46.
Zurück zum Zitat Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396. doi:10.1016/S0140-6736(97)10384-1 PubMedCrossRef Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396. doi:10.​1016/​S0140-6736(97)10384-1 PubMedCrossRef
47.
Zurück zum Zitat Goodwin PJ ClinicalTrials.gov—A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer NCT01101438, Accessed 18 Feb 2014 Goodwin PJ ClinicalTrials.gov—A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer NCT01101438, Accessed 18 Feb 2014
Metadaten
Titel
Associations between diabetes medication use and risk of second breast cancer events and mortality
verfasst von
Gregory S. Calip
Onchee Yu
Kent F. Hoskins
Denise M. Boudreau
Publikationsdatum
01.08.2015
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 8/2015
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-015-0599-z

Weitere Artikel der Ausgabe 8/2015

Cancer Causes & Control 8/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.